LONG-TERM CLINICAL OUTCOME OF PHYSIOLOGY-GUIDED RENAL ARTERY STENTING WITH ZETAROLIMUS ELUTING STENTS IN PATIENTS WITH UNCONTROLLED RENOVASCULAR HYPERTENSION
Verdiana Galli,Laura Trento,Federica Salfa,Simone Fezzi,Aurora Trevisanello,Enrico Galuppi,Matteo Casal,Matteo Piscopo,Roberto Scarsini,Gabriele Pesarini,Alessia Gambaro,Valeria Ferrero,Domenico Tavella,Flavio Luciano Ribichini
DOI: https://doi.org/10.1097/01.hjh.0001019756.67401.97
IF: 4.9
2024-05-01
Journal of Hypertension
Abstract:Objective: Randomized clinical trials (RCTs) failed to demonstrate the superiority of renal artery stenting (RAS) on optimal medical therapy (OMT) alone in terms of blood pressure (BP) control, renal function stabilization and cardiovascular events in patients with renal arteries stenosis (SRA). Main limitations of these trials are the lack of clear diagnostic criteria to identify hemodynamically significant SRA and the use of bare metal stents. Aim of the study was to assess safety and efficacy of RAS with new-generation zotarolimus-eluting stents in uncontrolled renovascular hypertension, after hemodynamic flow-limitation assessment by invasive pressure-wire (PW). Design and method: From 2012 to 2022, patients with suspected renovascular uncontrolled hypertension despite OMT and rapid renal function decline were enrolled. Lesions of at least intermediate angiographical significance were analyzed with PW measurements. A pressure ratio between the distality of the diseased vessel and the aortic pressure without hyperemia (Pd/Pa) below 0.9 was considered as potentially responsible of renal ischemia. In 21 patients out of 40 interrogated, 25 SRA yielded a Pd/Pa<0.9 and therefore treated with ZES implantation. Primary endpoint of the study was systolic and diastolic office blood pressure (OBP) variation at 2 years. Secondary endpoints included the impact of RAS on renal function and cardiovascular events. Results: Baseline average OBP was 160.0±22.4/84.7±9.8mmHg. At a median follow-up of 17 months, a significant OBP reduction was observed, respectively by -16,7±23.7mmHg (systolic, p=0.006) and -9,7±14.7mmHg (diastolic, p=0.01). Glomerular filtration rate confirmed to be stable with a trend towards improvement by +2.87±10.44 ml/min/1.73m2. No procedure-related complications were reported. During the follow-up period, two episodes of hypertensive crisis, two myocardial infarction and three admissions for acute renal impairment were reported. Conclusions: SRA is one of the most frequent causes of secondary hypertension, with high rates of clinical events. Previous RCTs yielded negative results in demonstrating benefits either on BP control or renal function. Our experience suggests that functional guidance to identify appropriate candidates for RAS can be effective. Moreover, this is the first cohort of RAS implanted with new-generation ZES, that may have further improved clinical results because of the reduced risk of restenosis.
peripheral vascular disease